High-density lipoproteins for the systemic delivery of short interfering RNA

Expert Opinion on Drug Delivery

Volumn 11, Issue 2, 2014, Pages 231-247

  McMahon, Kaylin Marie ^a,d   Thaxton, Colby Shad ^a,b,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Institute for BioNanotechnology and Medicine (IBNAM)   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Biomimetic; High density lipoprotein; Nanoparticle; RNA interference; Short interfering RNA; Targeted delivery

Indexed keywords

GOLD NANOPARTICLE; HIGH DENSITY LIPOPROTEIN; PHOSPHATE; RIBOSE; SMALL INTERFERING RNA; SUGAR; NANOPARTICLE;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; BIOLOGICAL FUNCTIONS; CHEMICAL MODIFICATION; CHOLESTEROL TRANSPORT; DRUG DELIVERY SYSTEM; HUMAN; ISCHEMIC HEART DISEASE; POLYMERIZATION; PROTEIN ANALYSIS; PROTEIN STRUCTURE; REVIEW; RNA INTERFERENCE; ANIMAL; CHEMISTRY; GENE SILENCING;

ANIMALS; GENE SILENCING; HUMANS; LIPOPROTEINS, HDL; NANOPARTICLES; RNA, SMALL INTERFERING;

EID: 84892747814     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2014.866089     Document Type: Review

References (116)

1. Guo PX, Coban O, Snead NM, et al. Engineering RNA for targeted siRNA delivery and medical application. Adv Drug Deliv Rev 2010;62(6):650-66
2. Weinstein S, Peer D. RNAi nanomedicines: challenges and opportunities within the immune system. Nanotechnology 2010;21(23):232001
3. Rana TM. Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol 2007;8(1):23-36
4. Watts JK, Deleavey GF, Damha MJ. Chemically modified siRNA: tools and applications. Drug Discov Today 2008;13(19-20):842-55
5. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411(6836):494-8
6. Kenski DM, Cooper AJ, Li JJ, et al. Analysis of acyclic nucleoside modifications in siRNAs finds sensitivity at position 1 that is restored by 5¢-terminal phosphorylation both in vitro and in vivo. Nucleic Acids Res 2010;38(2):660-71
7. Wang Y, Sheng G, Juranek S, et al. Structure of the guide-strand- containing argonaute silencing complex. Nature 2008;456(7219):209-13
8. Wang Y, Juranek S, Li H, et al. Structure of an argonaute silencing complex with a seed-containing guide DNA and target RNA duplex. Nature 2008;456(7224):921-6
9. Gaglione M, Messere A. Recent progress in chemically modified siRNAs. Mini Rev Med Chem 2010;10(7):578-95
10. Manoharan M. RNA interference and chemically modified small interfering RNAs. Curr Opin Chem Biol 2004;8(6):570-9
11. Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 2010;9(1):57-67
12. Behlke MA. Chemical modification of siRNAs for in vivo use. Oligonucleotides 2008;18(4):305-19
13. Schutz CA, Juillerat-Jeanneret L, Mueller H, et al. Therapeutic nanoparticles in clinics and under clinical evaluation. Nanomedicine (Lond) 2013;8(3):449-67
14. Nguyen T, Menocal EM, Harborth J, Fruehauf JH. RNAi therapeutics: an update on delivery. Curr Opin Mol Ther 2008;10(2):158-67
15. Bumcrot D, Manoharan M, Koteliansky V, Sah DW. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2006;2(12):711-19
16. Vaishnaw AK, Gollob J, Gamba-Vitalo C, et al. A status report on RNAi therapeutics. Silence 2010;1(1):14
17. Pecot CV, Calin GA, Coleman RL, et al. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 2011;11(1):59-67
18. van Dongen S, Abreu-Goodger C, Enright AJ. Detecting microRNA binding and siRNA off-target effects from expression data. Nat Methods 2008;5(12):1023-5
19. Higuchi Y, Kawakami S, Hashida M. Strategies for in vivo delivery of siRNAs: recent progress. BioDrugs 2010;24(3):195-205
20. Miele E, Spinelli GP, Miele E, et al. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int J Nanomed 2012;7:3637-57
21. Gao Y, Liu XL, Li XR. Research progress on siRNA delivery with nonviral carriers. Int J Nanomed 2011;6:1017-25
22. Layzer JM, McCaffrey AP, Tanner AK, et al. In vivo activity of nuclease-resistant siRNAs. RNA 2004;10(5):766-71
23. Jackson AL, Burchard J, Leake D, et al. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 2006;12(7):1197-205
24. Chiu YL, Rana TM. siRNA function in RNAi: a chemical modification analysis. RNA 2003;9(9):1034-48
25. Czauderna F, Fechtner M, Dames S, et al. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res 2003;31(11):2705-16
26. Morrissey DV, Lockridge J, Shaw L, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Hepatology 2005;42(4):576A-A
27. Overhoff M, Sczakiel G. Phosphorothioate-stimulated uptake of short interfering RNA by human cells. Embo Rep 2005;6(12):1176-81
28. Czech MP, Aouadl M, Tesz GJ, et al. RNAi-based therapeutic strategies for metabolic disease. Nat Rev Endocrinol 2011;7473-84
29. Hall AHS, Wan J, Shaughnessy EE, et al. RNA interference using boranophosphate siRNAs: structureactivity relationships. Nucleic Acids Res 2004;32(20):5991-6000
30. Harborth J, Elbashir SM, Vandenburgh K, et al. Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic A 2003;13(2):83-105
31. Amarzguioui M, Holen T, Babaie E, Prydz H. Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res 2003;31(2):589-95
32. Braasch DA, Jensen S, Liu YH, et al. RNA interference in mammalian cells by chemically-modified RNA. Biochemistry 2003;42(26):7967-75
33. Chen QM, Butler D, Querbes W, et al. Lipophilic siRNAs mediate efficient gene silencing in oligodendrocytes with direct CNS delivery. J Control Release 2010;144(2):227-32
34. DiFiglia M, Sena-Esteves M, Chase K, et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci USA 2007;104(43):17204-9
35. Wolfrum C, Shi S, Jayaprakash KN, et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 2007;25(10):1149-57
36. Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004;432(7014):173-8
37. Moschos SA, Jones SW, Perry MM, et al. Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug Chem 2007;18(5):1450-9
38. Arima H, Yoshimatsu A, Ikeda H, et al. Folate-PEG-Appended Dendrimer Conjugate with alpha-Cyclodextrin as a Novel Cancer Cell-Selective siRNA Delivery Carrier. Mol Pharmaceut 2012;9(9):2591-604
39. Yu B, Zhao X, Lee LJ, Lee RJ. Targeted delivery systems for oligonucleotide therapeutics. AAPS J 2009;11(1):195-203
40. Zhou JH, Rossi JJ. Therapeutic potential of aptamer-siRNA conjugates for treatment of HIV-1. BioDrugs 2012;26(6):393-400
41. McNamara JO, Andrechek ER, Wang Y, et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 2006;24(8):1005-15
42. Rozema DB, Lewis DL, Wakefield DH, et al. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci USA 2007;104(32):12982-7
43. Nishina K, Unno T, Uno Y, et al. Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. Mol Ther 2008;16(4):734-40
44. Yuan X, Naguib S, Wu Z. Recent advances of siRNA delivery by nanoparticles. Expert Opin Drug Deliv 2011;8(4):521-36
45. Inaba S, Nagahara S, Makita N, et al. Atelocollagen-mediated systemic delivery prevents immunostimulatory adverse effects of siRNA in mammals. Mol Ther 2012;20(2):356-66
46. Wang Y, Li Z, Han Y, et al. Nanoparticle-based delivery system for application of siRNA in vivo. Curr Drug Metab 2010;11(2):182-96
47. Davis ME, Zuckerman JE, Choi CH, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010;464(7291):1067-70
48. Alameh M, Dejesus D, Jean M, et al. Low molecular weight chitosan nanoparticulate system at low N:P ratio for nontoxic polynucleotide delivery. Int J Nanomed 2012;7:1399-414
49. Singha K, Namgung R, Kim WJ. Polymers in small-interfering RNA delivery. Nucleic acid Ther 2011;21(3):133-47
50. Kesharwani P, Tekade RK, Gajbhiye V, et al. Cancer targeting potential of some ligand-anchored poly(propylene imine) dendrimers: a comparison. Nanomedicine 2011;7(3):295-304
51. Taratula O, Garbuzenko OB, Kirkpatrick P, et al. Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. J Control Release 2009;140(3):284-93
52. Rossi JJ. RNAi therapeutics: SNALPing siRNAs in vivo. Gene Ther 2006;13(7):583-4
53. Akinc A, Querbes W, De S, et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligandbased mechanisms. Mol Ther 2010;18(7):1357-64
54. Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006;441(7089):111-14
55. Geisbert TW, Lee AC, Robbins M, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 2010;375(9729):1896-905
56. Lobovkina T, Jacobson GB, Gonzalez-Gonzalez E, et al. In vivo sustained release of siRNA from solid lipid nanoparticles. ACS Nano 2011;5(12):9977-83
57. Lee JM, Yoon TJ, Cho YS. Recent developments in nanoparticle-based siRNA delivery for cancer therapy. Biomed Res Int 2013;2013:782041
58. Zhang Z, Yang X, Zhang Y, et al. Delivery of telomerase reverse transcriptase small interfering RNA in complex with positively charged singlewalled carbon nanotubes suppresses tumor growth. Clin Cancer Res 2006;12(16):4933-9
59. Podesta JE, Al-Jamal KT, Herrero MA, et al. Antitumor activity and prolonged survival by carbon-nanotube-mediated therapeutic siRNA silencing in a human lung xenograft model. Small 2009;5(10):1176-85
60. Liu Z, Tabakman S, Welsher K, Dai HJ. Carbon nanotubes in biology and medicine: in vitro and in vivo detection, imaging and drug delivery. Nano Res 2009;2(2):85-120
61. Shvedova AA, Kisin ER, Porter D, et al. Mechanisms of pulmonary toxicity and medical applications of carbon nanotubes: two faces of Janus? Pharmacol Ther 2009;121(2):192-204
62. Firme CP III, Bandaru PR. Toxicity issues in the application of carbon nanotubes to biological systems. Nanomedicine 2010;6(2):245-56
63. Poland CA, Duffin R, Kinloch I, et al. Carbon nanotubes introduced into the abdominal cavity of mice show asbestoslike pathogenicity in a pilot study. Nat Nanotechnol 2008;3(7):423-8
64. Medarova Z, Pham W, Farrar C, et al. In vivo imaging of siRNA delivery and silencing in tumors. Nat Med 2007;13(3):372-7
65. Lee JH, Lee K, Moon SH, et al. All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery. Angew Chem Int Ed Engl 2009;48(23):4174-9
66. Yu Y, Sun D. Superparamagnetic iron oxide nanoparticle 'theranostics' for multimodality tumor imaging, gene delivery, targeted drug and prodrug delivery. Expert Rev Clin Pharmacol 2010;3(1):117-30
67. Su Y, He Y, Lu H, et al. The cytotoxicity of cadmium based, aqueous phase-synthesized, quantum dots and its modulation by surface coating. Biomaterials 2009;30(1):19-25
68. Subramaniam P, Lee SJ, Shah S, et al. Generation of a library of non-toxic quantum dots for cellular imaging and siRNA delivery. Adv Mater 2012;24(29):4014-19
69. Ghosh P, Han G, De M, et al. Gold nanoparticles in delivery applications. Adv Drug Deliv Rev 2008;60(11):1307-15
70. Connor EE, Mwamuka J, Gole A, et al. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small 2005;1(3):325-7
71. Rosi NL, Giljohann DA, Thaxton CS, et al. Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science 2006;312(5776):1027-30
72. Giljohann DA, Seferos DS, Prigodich AE, et al. Gene regulation with polyvalent siRNA-nanoparticle conjugates. J Am Chem Soc 2009;131(6):2072-3
73. Zheng D, Giljohann DA, Chen DL, et al. Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation. Proc Natl Acad Sci USA 2012;109(30):11975-80
74. Kim ST, Chompoosor A, Yeh YC, et al. Dendronized gold nanoparticles for siRNA delivery. Small 2012;8(21):3253-6
75. Bonoiu AC, Mahajan SD, Ding H, et al. Nanotechnology approach for drug addiction therapy: gene silencing using delivery of gold nanorod-siRNA nanoplex in dopaminergic neurons. Proc Natl Acad Sci USA 2009;106(14):5546-50
76. Camont L, Chapman MJ, Kontush A. Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med 2011;17(10):594-603
77. Xu S, Laccotripe M, Huang X, et al. Apolipoproteins of HDL can directly mediate binding to the scavenger receptor SR-BI, an HDL receptor that mediates selective lipid uptake. J Lipid Res 1997;38(7):1289-98
78. Warnick GR, McNamara JR, Boggess CN, et al. Polyacrylamide gradient gel electrophoresis of lipoprotein subclasses. Clin Lab Med 2006;26(4):803-46
79. Tabet F, Rye KA. High-density lipoproteins, inflammation and oxidative stress. Clin Sci 2009;116(1-2):87-98
80. Damiano MG, Mutharasan RK, Tripathy S, et al. Templated high density lipoprotein nanoparticles as potential therapies and for molecular delivery. Adv Drug Deliv Rev 2013;65(5):649-62
81. Rosenson RS, Brewer HB, Chapman MJ, et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 2011;57(3):392-410
82. Asztalos BF, Tani M, Schaefer EJ. Metabolic and functional relevance of HDL subspecies. Curr Opin Lipidol 2011;22(3):176-85
83. Bonow RO. Braunwald's heart disease-a textbook of cardiovascular medicine. 9th edition. Elsevier Saunders; Philadelphia, PA: 2012
84. Ikonen E. Cellular cholesterol trafficking and compartmentalization. Nat Rev Mol Cell Biol 2008;9(2):125-38
85. Calabresi L, Gomaraschi M, Rossoni G, Franceschini G. Synthetic high density lipoproteins for the treatment of myocardial ischemia/reperfusion injury. Pharmacol Ther 2006;111(3):836-54
86. Silva RAGD, Huang R, Morris J, et al. Structure of apolipoprotein A-I in spherical high density lipoproteins of different sizes. Proc Natl Acad Sci USA 2008;105(34):12176-81
87. Segrest JP, Li L, Anantharamaiah GM, et al. Structure and function of apolipoprotein A-I and high-density lipoprotein. Curr Opin Lipidol 2000;11(2):105-15
88. Cheung MC, Albers JJ. Distribution of high-density lipoprotein particles with different apoprotein composition-particles with a-I and a-Ii and particles with a-I but no a-Ii. J Lipid Res 1982;23(5):747-53
89. Vickers KC, Palmisano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011;13(4):423-U182
90. Liu X, Suo R, Xiong SL, et al. HDL drug carriers for targeted therapy. Clin Chim Acta 2013;415:94-100
91. Vickers KC, Remaley AT. Functional diversity of HDL cargo. J Lipid Res 2013;doi: 10.1194/jlr.R035964
92. Pirillo A, Norata GD, Catapano AL. High-density lipoprotein subfractions. what the clinicians need to know. Cardiology 2013;124(2):116-25
93. Rader DJ, Alexander ET, Weibel GL, et al. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res 2009;50(Suppl):S189-94
94. Gomaraschi M, Ossoli A, Vitali C, Calabresi L. HDL and endothelial protection: examining evidence from HDL inherited disorders. Clin Lipidol 2013;8(3):361-70
95. Nicholls SJ, Dusting GJ, Cutri B, et al. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 2005;111(12):1543-50
96. Cockerill GW, Rye KA, Gamble JR, et al. High-density-lipoproteins inhibit cytokine-induced expression of endothelial-cell adhesion molecules. Arterioscl Throm Vas 1995;15(11):1987-94
97. Navab M, Imes SS, Hama SY, et al. Monocyte transmigration induced by modification of low-density-lipoprotein in cocultures of human aortic-wall cells is due to induction of monocyte chemotactic protein-1 synthesis and is abolished by high-density-lipoprotein. J Clin Invest 1991;88(6):2039-46
98. Kontush A, Chapman MJ. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr Opin Lipidol 2010;21(4):312-18
99. Davidson WS, Silva RAGD, Chantepie S, et al. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters relevance to antioxidative function. Arterioscl Throm Vas 2009;29(6):870-U234
100. Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ Res 2006;98(11):1352-64
101. Yuhanna IS, Zhu Y, Cox BE, et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med 2001;7(7):853-7
102. Furie B, Furie BC. Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol Med 2004;10(4):171-8
103. Farmer JA, Liao J. Evolving concepts of the role of high-density lipoprotein in protection from atherosclerosis. Curr Atheroscler Rep 2011;13(2):107-14
104. Naqvi TZ, Shah PK, Ivey PA, et al. Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation. Am J Cardiol 1999;84(9):1011-17
105. Calkin AC, Drew BG, Ono A, et al. Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation 2009;120(21):2095-104
106. Bijsterbosch MK, Rump ET, De Vrueh RLA, et al. Modulation of plasma protein binding and in vivo liver cell uptake of phosphorothioate oligodeoxynucleotides by cholesterol conjugation. Nucleic Acids Res 2000;28(14):2717-25
107. Lorenz C, Hadwiger P, John M, et al. Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg Med Chem Lett 2004;14(19):4975-7
108. Thaxton CS, Daniel WL, Giljohann DA, et al. Templated spherical high density lipoprotein nanoparticles. J Am Chem Soc 2009;131(4):1384-5
109. Luthi AJ, Zhang H, Kim D, et al. Tailoring of biomimetic high-density lipoprotein nanostructures changes cholesterol binding and efflux. ACS Nano 2012;6(1):276-85
110. McMahon KM, Mutharasan RK, Tripathy S, et al. Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery. Nano Lett 2011;11(3):1208-14
111. Zhang ZH, Chen J, Ding LL, et al. HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting. Small 2010;6(3):430-7
112. Yang M, Jin HL, Chen JA, et al. Efficient cytosolic delivery of siRNA using HDL-mimicking nanoparticles. Small 2011;7(5):568-73
113. Lacko AG, Nair M, Paranjape S, et al. High density lipoprotein complexes as delivery vehicles for anticancer drugs. Anticancer Res 2002;22(4):2045-9
114. Shahzad MM, Mangala LS, Han HD, et al. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia 2011;13(4):309-19
115. Ding Y, Wang W, Feng MQ, et al. A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy. Biomaterials 2012;33(34):8893-905
116. Nakayama T, Butler JS, Sehgal A, et al. Harnessing a physiologic mechanism for siRNA delivery with mimetic lipoprotein particles. Mol Ther 2012;20(8):1582-9